Published in final edited form as:

Basic Res Cardiol. ; 112(6): 65. doi:10.1007/s00395-017-0654-x.

Regulation of myocardial oxygen delivery in response to graded reductions in hematocrit: Role of K⁺ channels

Alexander M. Kiel^{1,2}, Adam G. Goodwill¹, Jillian N. Noblet¹, April L. Barnard¹, Daniel J. Sassoon¹, and Johnathan D. Tune¹

¹Department of Cellular & Integrative Physiology, Indiana University School of Medicine

²Weldon School of Biomedical Engineering, Purdue University

Abstract

This study was designed to identify mechanisms responsible for coronary vasodilation in response to progressive decreases in hematocrit. Isovolemic hemodilution was produced in open-chest, anesthetized swine via concurrent removal of 500 ml of arterial blood and the addition of 500 ml of 37°C saline or synthetic plasma expander (Hespan, 6% hetastarch in 0.9% sodium chloride). Progressive hemodilution with Hespan resulted in an increase in coronary flow from 0.39 ± 0.05 to 1.63 ± 0.16 ml/min/g ($P < 0.001$) as hematocrit was reduced from $32 \pm 1\%$ to $10 \pm 1\%$ ($P < 0.001$). Overall, coronary flow corresponded with the level of myocardial oxygen consumption, was dependent on arterial pressures ~ 60 mmHg, and occurred with little/no change in coronary venous PO₂. Anemic coronary vasodilation was unaffected by the inhibition of nitric oxide synthase (L-NAME: 25 mg/kg iv; $P = 0.92$) or voltage-dependent K⁺ (K_V) channels (4-aminopyridine: 0.3 mg/kg iv; $P = 0.52$). However, administration of the K_{ATP} channel antagonist (glibenclamide: 3.6 mg/kg iv) resulted in an $\sim 40\%$ decrease in coronary blood flow ($P < 0.001$) as hematocrit was reduced to $\sim 10\%$. These reductions in coronary blood flow corresponded with significant reductions in myocardial oxygen delivery at baseline and throughout isovolemic anemia ($P < 0.001$). These data indicate that vasodilator factors produced in response to isovolemic hemodilution converge on vascular smooth muscle glibenclamide-sensitive (K_{ATP}) channels to maintain myocardial oxygen delivery and that this response is not dependent on endothelial-derived nitric oxide production or pathways that mediate dilation via K_V channels.

Keywords

coronary; anemia; nitric oxide; K_V channels; K_{ATP} channels; swine

INTRODUCTION

The coronary circulation is tightly regulated in order to ensure adequate matching between myocardial oxygen delivery and metabolism. This control of coronary blood flow is

Correspondence: Johnathan D. Tune, PhD, Department of Cellular & Integrative Physiology, Indiana University School of Medicine, 635 Barnhill Drive, Indianapolis, IN 46202, Phone: 317-274-3433, jtune@iu.edu.

CONFLICT OF INTEREST

The authors declare that they have no conflict of interest.

essential as the myocardium extracts ~70-80 percent of the oxygen delivered while at rest [18, 19, 40, 50]. Thus, any physiologic perturbation that alters the overall balance between oxygen delivery and myocardial oxygen consumption (MVO_2) requires the subsequent modulation of coronary microvascular resistance to ensure oxygen supply/demand balance. As such, the coronary circulation has a remarkable ability to increase blood flow upwards of 10-fold (from ~0.5 ml/min/g at rest to 5.0 ml/min/g with maximal dilation) [63]. Although this intricate coupling has been recognized for many years, our understanding of the underlying mechanisms remains rather limited.

Prior studies to examine the balance between coronary blood flow and MVO_2 have established that coronary blood flow increases exponentially (>4-fold) with ~70% reductions in arterial oxygen content in response to hemodilution (anemia), hypoxemia, and carbon monoxide poisoning [9, 29, 36, 37, 39, 43, 54, 64, 66, 71]. This progressive augmentation of coronary flow maintains overall myocardial oxygen delivery and occurs with a ~2-fold increase in MVO_2 and little/no change in myocardial oxygen extraction [10, 19, 34, 35, 47, 64, 67, 68]. However, evidence of enhanced myocardial lactate release and impairments to both sub-endocardial blood flow and cardiac contractile function have been reported with more severe reductions in hematocrit (< 10%) [1, 3, 37, 45, 64]. Earlier studies have suggested a role for reduced blood viscosity in the coronary response to anemia [5, 31, 33, 46, 62]. However, data demonstrating diminished vasodilator reserve to hemodilution in the presence of a critical coronary stenosis or in response to a brief coronary occlusion (i.e. reactive hyperemia) directly implicate that progressive reductions in hematocrit lead to the activation of vasodilator pathways [7, 9, 22, 31, 37, 67]. Nonetheless, elucidation of the mechanisms responsible for anemic coronary vasodilation has proven challenging. In particular, circulating catecholamine concentrations are not significantly altered by reductions in hematocrit to ~9% [64] and consequently, increases in coronary blood flow observed during β -adrenoceptor blockade are sufficient to sustain myocardial oxygen delivery thereby reducing the likelihood that these effects are sympathetically mediated [11]. Inhibition of nitric oxide production with N^G -nitro-L-arginine methyl ester (L-NAME) was also found to have little/no effect of the coronary blood flow in response to acute, euvoletic reductions in hematocrit from 40% to 20% [8]. However, whether nitric oxide contributes to the coronary dilator response as hematocrit is reduced below 20% has not been determined. Alternatively, end-effector K^+ channels in vascular smooth muscle are regulated by a variety of influences including endogenous endothelial and metabolic factors [25], cellular energy status (ATP/ADP ratio) [13, 25, 48], redox-dependent signaling [53], and the overall degree of oxygenation [21, 28]. Yet, whether these channels contribute to the balance between myocardial oxygen delivery and metabolism in response to progressive hemodilution has not been determined.

The purpose of this study was to identify mechanisms responsible for coronary vasodilation and the maintenance of myocardial oxygen delivery in response to moderate and severe reductions in hematocrit. Experiments were designed to test the hypothesis that the contributions of nitric oxide, voltage-dependent (K_V), and/or ATP-sensitive (K_{ATP}) K^+ channels progressively increase in response to acute isovolemic hemodilution in open-chest, anesthetized domestic swine. Our findings provide novel insight into the end-effector channels required for anemic coronary vasodilation.

METHODS

All experiments involving animals were approved by an Institutional Animal Care and Use Committee and performed in accordance with the Guide for the Care and Use of Laboratory Animals (NIH Publication No. 85-23, Revised 2011). Lean adult male domestic swine (n = 29) were sedated with telazol, xylazine, and ketamine (5, 2.5, and 2.5 mg/kg) prior to anesthesia with morphine (0.5 mg/kg) and intravenous α -chloralose (60 mg/kg).

Experimental preparation

Anesthetized swine were intubated and ventilated with O₂-supplemented room air. Femoral cut downs were performed and catheters placed in the femoral artery and vein for continuous measurement of systemic blood pressure and heart rate and for administration of anesthetic and antagonists, respectively. Succinylcholine (0.5 mg/kg) was administered prior to a thoracotomy in the left 5th intercostal space. The left anterior descending (LAD) coronary artery was isolated and a perivascular flow probe (Transonic Systems Inc.) placed around the artery. A catheter was placed in the interventricular vein to sample coronary venous blood. Systemic heparin (500 units/kg) was administered to prevent clotting in the coronary venous catheter. Following a ~15 min stabilization period, data were continuously recorded on IOX data acquisition software from EMKA Technologies (Falls Church, VA).

Acute isovolemic anemia protocol

Pigs were randomly assigned to one of the following six groups: 1) Control with saline replacement; 2) Control with Hespan (hydroxyethyl starch) replacement; 3) nitric oxide synthesis inhibition with nitro-L-arginine methyl ester (L-NAME, 25 mg/kg iv with Hespan replacement); 4) K_v channel inhibition with 4-aminopyridine (4-AP, 0.3 mg/kg iv with Hespan replacement); 5) K_{ATP} channel inhibition glibenclamide (3.6 mg/kg with Hespan replacement); 6) glibenclamide vehicle (equal parts 95% ethanol, 1N NaOH, propylene glycol). Following administration of drugs (for groups 3-6) and the ~15 min stabilization period of the animal, arterial and coronary venous blood samples were obtained at baseline and at stepwise serial reductions in hematocrit. Progressive isovolemic anemia was produced by withdrawing 500 ml of arterial blood that was simultaneously replaced by intravenous administration of 500 ml of saline or Hespan, which were warmed to 37°C prior to infusion. Following completion of experimental protocols, hearts were fibrillated and excised as recommended by the American Veterinary Medical Association Guide on Euthanasia.

Blood gas analyses

Arterial and coronary venous blood samples were collected, immediately sealed and placed on ice. The samples were analyzed for pH, PCO₂, PO₂, glucose, lactate, and oxygen content with an Instrumentation Laboratories automatic blood gas analyzer (GEM Premier 3000) and CO-oximeter (682) system. Hematocrit was determined by centrifugation of capillary tubes containing blood collected at each replacement on a StatSpin micro-hematocrit centrifuge (CritSpin M961-22). LAD perfusion territory was estimated to be 30% of total heart weight, as previously described by Feigl [20]. MVO₂ was calculated by multiplying coronary blood flow by the arterial coronary venous difference in oxygen content.

Statistical analysis

Data are presented as mean $\pm$ SE. Statistical comparisons for data presented in Tables 1 and 2 were made by a two-way analysis of variance (ANOVA; Factor A: drug treatment; Factor B: level of hematocrit). Experimental variables were averaged within and between animals relative to the following hematocrit levels: (~ 28.0) $\rightarrow$ ($27.9 - 22.0$) $\rightarrow$ ($21.9 - 17.0$) $\rightarrow$ ($16.9 - 11.0$) $\rightarrow$ (~ 10.9). Differences were considered statistically significant when $P < 0.05$. If significance with ANOVA was detected, a Student–Newman–Keuls multiple comparison test was performed. The relationship between coronary blood flow and hematocrit was fit to an inverse, second-order equation for each animal and a statistical comparison (t-test) of the predicted coronary flow based on the fit equation was performed at hematocrits of 10%, 20% and 30% to establish differences in relationships between treatments. Multiple linear regression analysis was used to compare slopes of response variables (oxygen delivery, coronary venous PO_2) plotted vs. hematocrit or MVO_2 . If the slopes of the regression lines were not significantly different, an analysis of covariance (ANCOVA) was used to adjust response variables for linear dependence on hematocrit or MVO_2 . Statistical analyses were performed with Sigma Plot 11.0 software (Systat Software Inc., San Jose, CA, USA), ANCOVA analyses were performed with VassarStats (Arlington, New York, USA).

RESULTS

Control responses to isovolemic hemodilution

Hemodynamic and coronary responses to graded reductions in hematocrit in untreated control swine that received volume replacement with saline or the synthetic colloid Hespan (hydroxyethyl starch) are shown in Figure 1. Saline based isovolemic hemodilution produced significant decreases in blood pressure (from 74 ± 6 mmHg to 26 ± 2 mmHg; Figure 1A; $P < 0.01$) and MVO_2 (from 61 ± 4 to 27 ± 4 ml O_2 /min/g; Figure 1B; $P < 0.01$). These reductions were associated with minimal change in coronary blood flow (0.49 ± 0.02 to 0.40 ± 0.06 ml/min/g; Figure 1C; $P = 0.63$) and marked decreases in myocardial oxygen delivery (78 ± 4 to 36 ± 6 ml O_2 /min/g; Figure 1D; $P < 0.001$) as hematocrit was reduced from $\sim 35\%$ to $\sim 15\%$. In contrast, aortic blood pressure (Figure 1A) and MVO_2 (Figure 1B) were not significantly altered by hemodilution in swine that received Hespan (Table 1). With the relative maintenance of blood pressure and MVO_2 , coronary blood flow increased ~ 4 -fold as hematocrit was reduced to 10% (Figure 1C and Table 1). This increase in coronary blood flow was sufficient to maintain myocardial oxygen delivery at $\sim 53 \pm 5$ μ l O_2 /min/g (Figure 1D). However, examination of electrocardiograms revealed evidence of sub-endocardial ischemia (ST segment depression and T wave inversion) under these conditions (Figure 2).

Examination of coronary responses relative to changes in aortic pressure (i.e. coronary perfusion pressure), heart rate, and MVO_2 are provided in Figure 3. These relationships demonstrate that coronary blood flow (Figure 3A) remained relatively constant over a wide range of blood pressures, down to ~ 40 mmHg, in swine that received saline replacement. However, myocardial oxygen delivery progressively decreased as aortic pressure fell with hemodilution in these animals (Figure 3B). In contrast, coronary vasodilation in response to

isovolemic hemodilution in Hespan infused animals was not influenced by underlying changes in aortic pressure (Figure 3A) but was directly related to increases in heart rate (Figure 3C) and MVO₂ (Figure 3D). Interestingly, coronary venous PO₂ remained unchanged with reductions in hematocrit (Figure 3E; $P = 0.97$) and was unaffected by underlying differences in MVO₂ in swine that received Hespan (Figure 3F; $P = 0.90$). In contrast, coronary venous PO₂ decreased as MVO₂ increased in swine that received saline replacement (Figure 3F; $P < 0.01$).

Role of nitric oxide in anemic coronary vasodilation

Inhibition of nitric oxide synthase with L-NAME resulted in a significant increase in mean arterial pressure from 92 ± 4 to 124 ± 6 mmHg (Table 1; $P < 0.001$) at baseline. This was associated with a significant increase in MVO₂, from 41 ± 4 to 50 ± 5 $\mu\text{l O}_2/\text{min/g}$ (Table 1; $P = 0.013$) at baseline. These effects of nitric oxide inhibition were evident throughout the isovolemic anemia protocol. Despite these hemodynamic effects, inhibition of nitric oxide did not affect coronary blood flow (Figure 4A; $P = 0.36$), myocardial oxygen delivery (Figure 4B; $P = 0.92$), or heart rate (Table 1; $P = 0.521$) as hematocrit was decreased from $32 \pm 2\%$ to $9 \pm 1\%$. However, administration of L-NAME diminished coronary venous PO₂ (Table 1; $P = 0.002$), primarily at higher hematocrits (Figure 4C; $P < 0.01$) and levels of MVO₂ (Figure 4D; $P = 0.03$).

Role of K_V and K_{ATP} channels in anemic coronary vasodilation

Blockade of K_V channels with 4-AP did not significantly affect blood pressure ($P = 0.097$), heart rate ($P = 0.195$), or MVO₂ ($P = 0.38$) as hematocrit was reduced from $33 \pm 1\%$ to $8 \pm 1\%$ (Table 1). Inhibition of K_V channels also did not significantly alter coronary blood flow (Figure 5A; $P = 0.21$) or myocardial oxygen delivery (Figure 5B; $P = 0.63$) at baseline or in response to isovolemic anemia. In contrast, 4-AP significantly decreased coronary venous PO₂ (Table 1; $P < 0.001$) irrespective of underlying hematocrit (Figure 5C; $P < 0.001$) or MVO₂ (Figure 5D; $P < 0.001$).

Inhibition of K_{ATP} channels with glibenclamide had no effect on blood pressure ($P = 0.541$) or heart rate ($P = 0.139$), however, MVO₂ decreased ~35% relative to vehicle-control swine, irrespective of underlying hematocrit (Table 2; $P < 0.001$). Administration of glibenclamide induced significant decreases in coronary blood flow (Table 2; $P < 0.001$) as hematocrit was reduced from $32 \pm 1\%$ to $9 \pm 1\%$ (Figure 6A; $P < 0.001$). These reductions in coronary blood flow corresponded with significant reductions in myocardial oxygen delivery at baseline and throughout isovolemic anemia (Figure 6B; $P < 0.001$). Glibenclamide also significantly decreased coronary venous PO₂, (Table 2; Figure 6C; $P = 0.003$) but did not significantly alter the relationship between coronary venous PO₂ and MVO₂ (Figure 6D; $P = 0.36$).

DISCUSSION

This investigation was designed to identify mechanisms responsible for coronary vasodilation and the maintenance of myocardial oxygen delivery in response to moderate and severe reductions in hematocrit. Experiments tested the hypothesis that the contribution

of nitric oxide, K_V , and/or K_{ATP} channels increase in response to acute isovolemic hemodilution in open-chest, anesthetized domestic swine. Our findings are consistent with prior studies which have demonstrated that progressive augmentation of coronary blood flow in response to anemia is sufficient to maintain overall myocardial oxygen delivery, although subendocardial ischemia is apparent as hematocrit falls to $\sim 10\%$ [1, 3, 37, 45, 64]. Overall, coronary blood flow corresponds with MVO_2 , is dependent on arterial driving pressures ~ 60 mmHg, and occurs with little/no change in myocardial oxygen extraction (coronary venous PO_2) [10, 19, 34, 35, 47, 64, 67, 68]. The major novel findings of this study are that inhibition of K_{ATP} channels with glibenclamide significantly attenuates anemic coronary vasodilation and that this response occurs independent of alterations in endothelial nitric oxide production or the activation of K_V channels. These data are the first to implicate that vasodilator factors produced in response to graded reductions in hematocrit (arterial oxygen content) converge on vascular smooth muscle glibenclamide-sensitive K_{ATP} channels to mediate increases in coronary blood flow and maintain myocardial oxygen delivery.

Myocardial Oxygen Supply/Demand Balance During Acute Isovolemic Anemia

It is well established that reductions in hematocrit lead to marked hemodynamic responses including increases in cardiac output, heart rate, contractility, and MVO_2 [8, 30, 37, 64], all of which are important determinants of coronary blood flow [25]. In the present study, we noted significant differences in the coronary response to hemodilution in swine that received volume replacement with saline vs Hespan. We propose that the lack of a change in coronary blood flow to progressive anemia in the saline group (Figure 1C) is most likely due to marked reductions in arterial pressure which fell beyond the normal autoregulatory range at relatively high ($\sim 30\%$) hematocrits (Figure 1A; Figure 3A). These findings support that adequate coronary perfusion pressure (~ 60 mmHg) is required to ensure the maintenance of myocardial oxygen delivery in response to progressive reductions in hematocrit. Importantly, when arterial pressure is maintained by volume replacement with Hespan, increases in coronary blood flow are directly related to the degree of hemodilution (Figure 1) and reductions in coronary vascular resistance. The central question surrounding this phenomenon is “how” changes in hematocrit induce increases in coronary blood flow precisely to the degree necessary to preserve myocardial oxygen delivery.

The simplest explanation for reductions in coronary vascular resistance in response to anemia is a reduction of blood viscosity. While analysis of vascular hindrance (resistance/viscosity) supports a role for viscosity at hematocrits ranging from $\sim 60\%$ to 20% [33], studies which have documented diminished vasodilator reserve to hemodilution in the presence of a critical coronary stenosis or in response to a brief coronary occlusion (i.e. reactive hyperemia) directly demonstrate that progressive reductions in hematocrit lead to the activation of vasodilator pathways [7, 9, 22, 31, 37, 67]. We propose that the discrepant coronary responses to volume replacement with saline are not related to differences in the viscosity as the lower dynamic viscosity of saline vs. Hespan would be predicted to augment the overall degree of anemic coronary vasodilation. However, reductions in arterial pressure in swine that received saline confound interpretation of the role of viscosity.

Although it is apparent that coronary vasodilation occurs in response to anemia, the mechanisms responsible for anemic coronary dilation have remained elusive. More specifically, how changes in hematocrit are sensed is simply not understood. Classically, changes in myocardial tissue PO_2 , which are indexed by changes in coronary venous PO_2 , are proposed to invoke the production of vasodilator factors that act to increase coronary blood flow and restore tissue PO_2 to normal levels via negative feedback loop [25]. However, the consistency of coronary venous PO_2 (myocardial oxygen extraction) as hematocrit is lowered to $< 10\%$ (Figure 3) has been found in rats [69], dogs [7, 12, 37, 61], pigs [64], baboons [68], and humans [24] and directly argues against this traditional paradigm. How and why coronary venous PO_2 remains unchanged, even during severe hemodilution when ischemia is evident, is still yet another mystery. Proposed mechanisms for this paradoxical response include the flow-limited diffusion of oxygen, alterations in oxygen binding properties of blood due to altered plasma protein and buffer content, and the diminished release of oxygen by erythrocytes due to reduced intracellular convection [37, 67].

Role for Nitric Oxide in Anemic Coronary Vasodilation

Nitric oxide is an endothelial-derived vasodilating factor whose release is stimulated by pharmacological agonists (e.g. acetylcholine and bradykinin) and mechanical stimulation of the endothelium via shear stress, pulsatile flow, and/or axial strain [4, 38, 58, 59]. Prior studies also indicate that nitric oxide is scavenged and transported by hemoglobin in the form of S-nitrosohemoglobin [41, 57]. To examine the role of nitric oxide in the regulation of coronary blood flow during progressive reductions in hematocrit, we performed isovolemic hemodilution experiments in the absence and presence of the nitric oxide synthase blocker L-NAME. While the inhibition of nitric oxide production resulted in significant (> 25 mmHg) increases in blood pressure (Table 1) and increased myocardial oxygen extraction at higher hematocrits ($> 20\%$) (Figure 4C), L-NAME had essentially no effect on coronary blood flow (Figure 4A) or myocardial oxygen delivery (Figure 4B) at hematocrits ranging from $\sim 30\%$ to $\sim 10\%$. These data are consistent with the prior studies by Crystal *et al.* in dogs which documented no effect of intracoronary L-NAME on anemic coronary vasodilation down to hematocrits of $\sim 20\%$ [8]. Importantly, the use of intracoronary L-NAME prevented changes in systemic blood pressure and thus argue against hypertension as a confounding influence in the present study. The lack of effect of either systemic or intracoronary L-NAME demonstrates that alterations in nitric oxide bioavailability or endothelial shear stress do not play a significant role in modulating coronary blood flow in response to progressive isovolemic hemodilution.

Role for K^+ Channels in Anemic Coronary Vasodilation

K^+ channels dominate membrane conductance of coronary vascular smooth muscle and serve as important end-effector mechanisms of endogenous and exogenous vasodilator compounds [17, 25]. In particular, K_V channels have been shown to contribute to the control of coronary blood flow at rest, during increases in MVO_2 , and following a brief coronary artery occlusion [2, 16, 26, 27, 49, 53]. To test the hypothesis that anemic coronary vasodilation is mediated by endogenous factors that converge on K_V channels, we performed isovolemic hemodilution experiments in the absence and presence of the non-selective K_V

channel inhibitor 4-AP [51–53]. Similar to our results with L-NAME, we found that 4-AP diminished coronary venous PO₂ primarily at higher hematocrits (> 20%) (Table 1; Figure 5C). However, inhibition of K_V channels did not significantly influence anemic coronary vasodilation as 4-AP had no effect on coronary blood flow (Figure 5A), myocardial oxygen delivery (Figure 5B) in response to progressive hemodilution. Prior studies from our laboratory have documented that the 0.3 mg/kg dose used in this investigation is sufficient to significantly impair coronary vasodilation and the balance between myocardial oxygen delivery and metabolism in response to increases in MVO₂ and to a brief coronary artery occlusion [2, 16, 53]. These findings importantly demonstrate that 4-AP significantly reduces coronary blood flow, under specific physiological conditions, and indicate that the vasodilator “metabolites” produced in response to progressive anemia are different than those produced in response to exercise or acute myocardial ischemia. While we cannot rule out potential effects of 4-AP on cardiomyocytes or other K⁺ channel subtypes, it is noteworthy that 4-AP did not produce any changes in the ECG or MVO₂ (Table 1) and that similar doses of 4-AP do not significantly influence coronary vasodilation in response to the K_{ATP} channel agonist pinacidil [16]. Taken together, our findings do not support a requisite role for K_V channels, or the pathways that converge on these channels, in mediating coronary vasodilation in response to hemodilution.

K_{ATP} channels are highly expressed in coronary vascular smooth muscle and are known to be activated by cellular energetic state (ATP/ADP ratio), intracellular pH, and by pathophysiologic conditions such as hypoxia and ischemia [14, 17]. However, whether isovolemic hemodilution mediates coronary vasodilation via activation of K_{ATP} channels has not been previously investigated. Data from this study are the first to demonstrate that the inhibition of K_{ATP} channels with glibenclamide markedly diminishes increases in coronary blood flow (Figure 6A) and myocardial oxygen delivery (Figure 6B) in response to progressive reductions in hematocrit. It is important to point out that glibenclamide significantly decreased MVO₂ by ~45-50% at all levels of hematocrit (Table 2) and that such reductions in MVO₂ could result in decreases in coronary blood flow, possibly via effects on mitochondrial K_{ATP} channels [25]. However, we propose that this is likely not the case as the progressive reduction of the coronary blood flow response to decreases in hematocrit in glibenclamide treated swine (Figure 6A) does not correspond with augmented decreases in MVO₂ (Table 2). Furthermore, the Bache laboratory previously documented that glibenclamide-mediated reductions in MVO₂ are restored to normal levels by increasing coronary blood flow with intracoronary sodium nitroprusside [32]. This finding combined with additional evidence that the mitochondrial K_{ATP} channel antagonist 5-hydroxydecanoate (5-HD) has no effect on MVO₂ supports that glibenclamide-mediated decreases in MVO₂ are the result of coronary vasoconstriction (limitation of myocardial oxygen delivery) rather than primary reductions in mitochondrial respiration per se [6]. However, we acknowledge that we cannot definitively rule out effects of glibenclamide on sarcolemmal or mitochondrial channels in cardiomyocytes and/or the potential for glibenclamide to antagonize other K⁺ channel subtypes (e.g. IK₁ and K_{V1}) [56, 70]. Despite the potential for these confounding influences, findings from this investigation directly support that anemia results in the production of factors that mediate coronary dilation via pathways that converge on glibenclamide-sensitive (K_{ATP}) channels.

The mechanisms responsible for the activation of K_{ATP} channels during hemodilution are yet to be determined. While prior studies indicate that hypoxia-induced hyperpolarization of vascular smooth muscle and vasodilation is diminished by glibenclamide [21], data from the Gutterman laboratory indicate that the direct vasodilator effect of hypoxia on isolated coronary arterioles occurs over a time period of 10-15 min [44]; i.e. development of smooth muscle hypoxia is unlikely to contribute to anemic coronary vasodilation. Evidence of overt myocardial ischemia (ST segment depression, T wave inversion, myocardial lactate release) and contractile dysfunction following more severe reductions in hematocrit ($\sim 10\%$) implicates the activation of ischemic vasodilator pathways such as adenosine could be involved. This hypothesis is supported by earlier studies which have established that myocardial adenosine release increases exponentially with the severity of hypoxia [15, 29, 60, 65] and that the inhibition of adenosine receptors reduces hypoxic coronary vasodilation by $\sim 20\text{-}25\%$ [23, 42, 43, 55]. We propose that studies to examine the role of adenosine in response to progressive anemia should include inhibition of not only specific adenosine receptor subtypes (A1, A2A, A2B, and A3 receptors), but also involve experiments to interrogate the potential effects of other purine nucleotides (AMP, ADP), purinergic receptors (various P2Y subtypes), and potentially cyclooxygenase products. Furthermore, based on previous studies we hypothesize that unidentified factors (other than purinergic metabolites) are responsible for the majority ($\sim 75\text{-}80\%$) of anemic coronary vasodilation.

IMPLICATIONS AND CONCLUSIONS

Data from this study highlight many unanswered questions that remain central to the field of coronary physiology. Namely, how alterations in myocardial oxygen supply and/or MVO_2 are ultimately sensed and regulated. With regard to the coronary response to anemia, it is particularly intriguing that coronary blood flow increases precisely to the degree necessary to maintain oxygen delivery, and that this preservation occurs without a decrease in coronary venous PO_2 (increase in myocardial oxygen extraction). These findings indicate that reductions in myocardial tissue PO_2 are not required for maintaining myocardial oxygen supply/demand balance and suggest that other “oxygen sensing” mechanisms could be at play. While the present data do not provide evidence to support how progressive reductions in hematocrit are sensed, they do directly implicate a significant role for glibenclamide-sensitive (K_{ATP}) channels in the response. Whether the involvement of these channels occurs directly via changes in the energy status of vascular smooth muscle and/or through the production of vasoactive factors that converge on these channels remains to be determined. Importantly, our findings also demonstrate that the anemic coronary vasodilation is not dependent on endothelial-derived nitric oxide production or involve pathways that converge on smooth muscle K_V channels.

Acknowledgments

The authors wish to thank Joshua Sturek for expert technical assistance. This study was supported by U01HL118738.

References

1. Bagger H. Distribution of maximum coronary blood flow in the left ventricular wall of anesthetized dogs. *Acta Physiol Scand.* 1978; 104:48–60. DOI: 10.1111/j.1748-1716.1978.tb06250.x [PubMed: 151482]
2. Berwick ZC, Dick GM, Moberly SP, Kohr MC, Sturek M, Tune JD. Contribution of voltage-dependent K(+) channels to metabolic control of coronary blood flow. *J Mol Cell Cardiol.* 2012; 52:912–919. DOI: 10.1016/j.yjmcc.2011.07.004 [PubMed: 21771599]
3. Brazier J, Cooper N, Buckberg G. The adequacy of subendocardial oxygen delivery: the interaction of determinants of flow, arterial oxygen content and myocardial oxygen need. *Circulation.* 1974; 49:968–977. DOI: 10.1161/01.CIR.49.5.968 [PubMed: 4597569]
4. Canty JM Jr, Schwartz JS. Nitric oxide mediates flow-dependent epicardial coronary vasodilation to changes in pulse frequency but not mean flow in conscious dogs. *Circulation.* 1994; 89:375–384. DOI: 10.1161/01.CIR.89.1.375 [PubMed: 8281673]
5. Case RB, Berglund E, Sarnoff SJ. Ventricular function. VII. Changes in coronary resistance and ventricular function resulting from acutely induced anemia and the effect thereon of coronary stenosis. *Am J Med.* 1955; 18:397–405. DOI: 10.1016/0002-9343(55)90219-9 [PubMed: 14349964]
6. Chen Y, Traverse JH, Zhang J, Bache RJ. Selective blockade of mitochondrial K(ATP) channels does not impair myocardial oxygen consumption. *Am J Physiol Heart Circ Physiol.* 2001; 281:H738–744. [PubMed: 11454578]
7. Crystal GJ. Coronary hemodynamic responses during local hemodilution in canine hearts. *Am J Physiol.* 1988; 254:H525–531. [PubMed: 3348430]
8. Crystal GJ, El-Orbany M, Zhou X, Salem MR, Kim SJ. Hemodilution does not alter the coronary vasodilating effects of endogenous or exogenous nitric oxide. *Can J Anaesth.* 2008; 55:507–514. DOI: 10.1007/BF03016670 [PubMed: 18676385]
9. Crystal GJ, Kim SJ, Salem MR. Right and left ventricular O₂ uptake during hemodilution and beta-adrenergic stimulation. *Am J Physiol.* 1993; 265:H1769–1777. [PubMed: 8238590]
10. Crystal GJ, Rooney MW, Salem MR. Regional hemodynamics and oxygen supply during isovolemic hemodilution alone and in combination with adenosine-induced controlled hypotension. *Anesth Analg.* 1988; 67:211–218. DOI: 10.1213/00000539-198803000-00002 [PubMed: 3344974]
11. Crystal GJ, Ruiz JR, Rooney MW, Salem MR. Regional hemodynamics and oxygen supply during isovolemic hemodilution in the absence and presence of high-grade beta-adrenergic blockade. *J Cardiothorac Anesth.* 1988; 2:772–779. DOI: 10.1016/0888-6296(88)90101-9 [PubMed: 17171887]
12. Crystal GJ, Salem MR. Myocardial and systemic hemodynamics during isovolemic hemodilution alone and combined with nitroprusside-induced controlled hypotension. *Anesth Analg.* 1991; 72:227–237. DOI: 10.1213/00000539-199102000-00016 [PubMed: 1898689]
13. Dart C, Standen NB. Activation of ATP-dependent K⁺ channels by hypoxia in smooth muscle cells isolated from the pig coronary artery. *J Physiol.* 1995; 483(Pt 1):29–39. DOI: 10.1113/jphysiol.1995.sp020565 [PubMed: 7539841]
14. Dart C, Standen NB. Adenosine-activated potassium current in smooth muscle cells isolated from the pig coronary artery. *J Physiol.* 1993; 471:767–786. DOI: 10.1113/jphysiol.1993.sp019927 [PubMed: 7509875]
15. Deussen A, Borst M, Kroll K, Schrader J. Formation of S-adenosylhomocysteine in the heart. II: A sensitive index for regional myocardial underperfusion. *Circ Res.* 1988; 63:250–261. DOI: 10.1161/01.RES.63.1.250 [PubMed: 3383379]
16. Dick GM, Bratz IN, Borbouse L, Payne GA, Dincer UD, Knudson JD, Rogers PA, Tune JD. Voltage-dependent K⁺ channels regulate the duration of reactive hyperemia in the canine coronary circulation. *Am J Physiol Heart Circ Physiol.* 2008; 294:H2371–2381. DOI: 10.1152/ajpheart.01279.2007 [PubMed: 18375717]
17. Dick GM, Tune JD. Role of potassium channels in coronary vasodilation. *Exp Biol Med* (Maywood). 2010; 235:10–22. DOI: 10.1258/ebm.2009.009201 [PubMed: 20404014]

18. Duncker DJ, Bache RJ. Regulation of coronary blood flow during exercise. *Physiol Rev.* 2008; 88:1009–1086. DOI: 10.1152/physrev.00045.2006 [PubMed: 18626066]
19. Feigl EO. Coronary physiology. *Physiol Rev.* 1983; 63:1–205. [PubMed: 6296890]
20. Feigl EO, Neat GW, Huang AH. Interrelations between coronary artery pressure, myocardial metabolism and coronary blood flow. *J Mol Cell Cardiol.* 1990; 22:375–390. DOI: 10.1016/0022-2828(90)91474-L [PubMed: 2388275]
21. Gauthier-Rein KM, Bizub DM, Lombard JH, Rusch NJ. Hypoxia-induced hyperpolarization is not associated with vasodilation of bovine coronary resistance arteries. *Am J Physiol.* 1997; 272:H1462–1469. [PubMed: 9087625]
22. Geha AS. Coronary and cardiovascular dynamics and oxygen availability during acute normovolemic anemia. *Surgery.* 1976; 80:47–53. [PubMed: 1273767]
23. Gewirtz H, Olsson RA, Most AS. Role of adenosine in mediating the coronary vasodilative response to acute hypoxia. *Cardiovasc Res.* 1987; 21:81–89. DOI: 10.1093/cvr/21.2.81 [PubMed: 3664545]
24. Gisselsson L, Rosberg B, Ericsson M. Myocardial blood flow, oxygen uptake and carbon dioxide release of the human heart during hemodilution. *Acta Anaesthesiol Scand.* 1982; 26:589–591. DOI: 10.1111/j.1399-6576.1982.tb01820.x [PubMed: 6818813]
25. Goodwill AG, Dick GM, Kiel AM, Tune JD. Regulation of Coronary Blood Flow. *Compr Physiol.* 2017; 7:321–382. DOI: 10.1002/cphy.c160016 [PubMed: 28333376]
26. Goodwill AG, Fu L, Noblet JN, Casalini ED, Sassoon D, Berwick ZC, Kassab GS, Tune JD, Dick GM. KV7 channels contribute to paracrine, but not metabolic or ischemic, regulation of coronary vascular reactivity in swine. *Am J Physiol Heart Circ Physiol.* 2016; 310:H693–704. DOI: 10.1152/ajpheart.00688.2015 [PubMed: 26825518]
27. Goodwill AG, Noblet JN, Sassoon D, Fu L, Kassab GS, Schepers L, Herring BP, Rottgen TS, Tune JD, Dick GM. Critical contribution of KV1 channels to the regulation of coronary blood flow. *Basic Res Cardiol.* 2016; 111:56.doi: 10.1007/s00395-016-0575-0 [PubMed: 27496159]
28. Guarini G, Kiyooka T, Ohanyan V, Pung YF, Marzilli M, Chen YR, Chen CL, Kang PT, Hardwick JP, Kolz CL, Yin L, Wilson GL, Shokolenko I, Dobson JG Jr, Fenton R, Chilian WM. Impaired coronary metabolic dilation in the metabolic syndrome is linked to mitochondrial dysfunction and mitochondrial DNA damage. *Basic Res Cardiol.* 2016; 111:29.doi: 10.1007/s00395-016-0547-4 [PubMed: 27040114]
29. Herrmann SC, Feigl EO. Adrenergic blockade blunts adenosine concentration and coronary vasodilation during hypoxia. *Circ Res.* 1992; 70:1203–1216. DOI: 10.1161/01.RES.70.6.1203 [PubMed: 1315635]
30. Hirose Y, Kimura H, Kitahata H, Kawahito S, Oshita S. Nitric oxide does not play a major role in the regulation of systemic hemodynamic responses to acute normovolemic hemodilution. *Acta Anaesthesiol Scand.* 2000; 44:96–100. DOI: 10.1034/j.1399-6576.2000.440117.x [PubMed: 10669279]
31. Holtz J, Bassenge E, von Restorff W, Mayer E. Transmural differences in myocardial blood flow and in coronary dilatory capacity in hemodiluted conscious dogs. *Basic Res Cardiol.* 1976; 71:36–46. DOI: 10.1007/BF01907781 [PubMed: 1259684]
32. Ishibashi Y, Duncker DJ, Zhang J, Bache RJ. ATP-sensitive K⁺ channels, adenosine, and nitric oxide-mediated mechanisms account for coronary vasodilation during exercise. *Circ Res.* 1998; 82:346–359. DOI: 10.1161/01.RES.82.3.346 [PubMed: 9486663]
33. Jan KM, Chien S. Effect of hematocrit variations on coronary hemodynamics and oxygen utilization. *Am J Physiol.* 1977; 233:H106–113. [PubMed: 879327]
34. Khouri EM, Gregg DE, Rayford CR. Effect of exercise on cardiac output, left coronary flow and myocardial metabolism in the unanesthetized dog. *Circ Res.* 1965; 17:427–437. DOI: 10.1161/01.RES.17.5.427 [PubMed: 5843879]
35. Kuramoto K, Matsushita S, Matsuda T, Mifune J, Sakai M, Iwasaki T, Shinagawa T, Moroki N, Murakami M. Effect of hematocrit and viscosity on coronary circulation and myocardial oxygen utilization. *Jpn Circ J.* 1980; 44:443–448. DOI: 10.1253/jcj.44.443 [PubMed: 7401273]

36. Lee SC, Mallet RT, Shizukuda Y, Williams AG Jr, Downey HF. Canine coronary vasodepressor responses to hypoxia are attenuated but not abolished by 8-phenyltheophylline. *Am J Physiol.* 1992; 262:H955–960. [PubMed: 1566915]
37. Levy PS, Kim SJ, Eckel PK, Chavez R, Ismail EF, Gould SA, Ramez Salem M, Crystal GJ. Limit to cardiac compensation during acute isovolemic hemodilution: influence of coronary stenosis. *Am J Physiol.* 1993; 265:H340–349. [PubMed: 8342651]
38. Liu Y, Gutterman DD. Vascular control in humans: focus on the coronary microcirculation. *Basic Res Cardiol.* 2009; 104:211–227. DOI: 10.1007/s00395-009-0775-y [PubMed: 19190954]
39. Martinez RR, Setty S, Zong P, Tune JD, Downey HF. Nitric oxide contributes to right coronary vasodilation during systemic hypoxia. *Am J Physiol Heart Circ Physiol.* 2005; 288:H1139–1146. DOI: 10.1152/ajpheart.01139.2003 [PubMed: 15513958]
40. Laughlin, Maurice H., K, RJ., Duncker, Dirk J., Bache, Robert J. Control of Blood Flow to Cardiac and Skeletal Muscle During Exercise. *Compr Physiol Handbook of Physiology, Exercise: Regulation and Integration of Multiple Systems.* 1996; :705–769. DOI: 10.1002/cphy.cp120116
41. McMahon TJ, Stamler JS. Concerted nitric oxide/oxygen delivery by hemoglobin. *Methods Enzymol.* 1999; 301:99–114. DOI: 10.1016/S0076-6879(99)01073-3 [PubMed: 9919558]
42. Merrill GF, Downey HF, Jones CE. Adenosine deaminase attenuates canine coronary vasodilation during systemic hypoxia. *Am J Physiol.* 1986; 250:H579–583. [PubMed: 3963215]
43. Merrill GF, Downey HF, Yonekura S, Watanabe N, Jones CE. Adenosine deaminase attenuates canine coronary vasodilatation during regional non-ischaemic myocardial hypoxia. *Cardiovasc Res.* 1988; 22:345–350. DOI: 10.1093/cvr/22.5.345 [PubMed: 3191518]
44. Miura H, Wachtel RE, Loberiza FR Jr, Saito T, Miura M, Nicolosi AC, Gutterman DD. Diabetes mellitus impairs vasodilation to hypoxia in human coronary arterioles: reduced activity of ATP-sensitive potassium channels. *Circ Res.* 2003; 92:151–158. DOI: 10.1161/01.RES.0000052671.53256.49 [PubMed: 12574142]
45. Murakami H, Kim SJ, Lee SC, Strete D, Downey HF. Adenosine exacerbates ischemic myocardial injury during regional coronary hypoxemia in the dog. *Jpn Heart J.* 1990; 31:365–383. DOI: 10.1536/ihj.31.365 [PubMed: 2214137]
46. Murray JF, Escobar E, Rapaport E. Effects of blood viscosity on hemodynamic responses in acute normovolemic anemia. *Am J Physiol.* 1969; 216:638–642. [PubMed: 5765616]
47. Nelson RR, Gobel FL, Jorgensen CR, Wang K, Wang Y, Taylor HL. Hemodynamic predictors of myocardial oxygen consumption during static and dynamic exercise. *Circulation.* 1974; 50:1179–1189. DOI: 10.1161/01.CIR.50.6.1179 [PubMed: 4430113]
48. Nichols CG, Lederer WJ. Adenosine triphosphate-sensitive potassium channels in the cardiovascular system. *Am J Physiol.* 1991; 261:H1675–1686. [PubMed: 1750525]
49. Ohanyan V, Yin L, Bardakjian R, Kolz C, Enrick M, Hakobyan T, Kmetz J, Bratz I, Luli J, Nagane M, Khan N, Hou H, Kuppusamy P, Graham J, Fu FK, Janota D, Oyewumi MO, Logan S, Lindner JR, Chilian WM. Requisite Role of Kv1.5 Channels in Coronary Metabolic Dilation. *Circ Res.* 2015; 117:612–621. DOI: 10.1161/CIRCRESAHA.115.306642 [PubMed: 26224794]
50. Richardson RS, Poole DC, Knight DR, Kurdak SS, Hogan MC, Grassi B, Johnson EC, Kendrick KF, Erickson BK, Wagner PD. High muscle blood flow in man: is maximal O₂ extraction compromised? *J Appl Physiol* (1985). 1993; 75:1911–1916. [PubMed: 8282650]
51. Rogers PA, Chilian WM, Bratz IN, Bryan RM Jr, Dick GM. H₂O₂ activates redox- and 4-aminopyridine-sensitive Kv channels in coronary vascular smooth muscle. *Am J Physiol Heart Circ Physiol.* 2007; 292:H1404–1411. DOI: 10.1152/ajpheart.00696.2006 [PubMed: 17071731]
52. Rogers PA, Dick GM, Knudson JD, Focardi M, Bratz IN, Swafford AN Jr, Saitoh S, Tune JD, Chilian WM. H₂O₂-induced redox-sensitive coronary vasodilation is mediated by 4-aminopyridine-sensitive K⁺ channels. *Am J Physiol Heart Circ Physiol.* 2006; 291:H2473–2482. DOI: 10.1152/ajpheart.00172.2006 [PubMed: 16751285]
53. Saitoh S, Zhang C, Tune JD, Potter B, Kiyooka T, Rogers PA, Knudson JD, Dick GM, Swafford A, Chilian WM. Hydrogen peroxide: a feed-forward dilator that couples myocardial metabolism to coronary blood flow. *Arterioscler Thromb Vasc Biol.* 2006; 26:2614–2621. DOI: 10.1161/01.ATV.0000249408.55796.da [PubMed: 17023676]

54. Setty S, Zong P, Sun W, Tune JD, Downey HF. Hypoxia-induced vasodilation in the right coronary circulation of conscious dogs: role of adrenergic activation. *Auton Neurosci*. 2008; 138:76–82. DOI: 10.1016/j.autneu.2007.10.004 [PubMed: 18055275]
55. Shizukuda Y, Mallet RT, Lee SC, Downey HF. Hypoxic preconditioning of ischaemic canine myocardium. *Cardiovasc Res*. 1992; 26:534–542. DOI: 10.1093/cvr/26.5.534 [PubMed: 1446323]
56. Song Y, Srinivas M, Belardinelli L. Nonspecific inhibition of adenosine-activated K⁺ current by glibenclamide in guinea pig atrial myocytes. *Am J Physiol*. 1996; 271:H2430–2437. [PubMed: 8997302]
57. Stamler JS, Jia L, Eu JP, McMahon TJ, Demchenko IT, Bonaventura J, Gernert K, Piantadosi CA. Blood flow regulation by S-nitrosohemoglobin in the physiological oxygen gradient. *Science*. 1997; 276:2034–2037. DOI: 10.1126/science.276.5321.2034 [PubMed: 9197264]
58. Stepp DW, Merkus D, Nishikawa Y, Chilian WM. Nitric oxide limits coronary vasoconstriction by a shear stress-dependent mechanism. *Am J Physiol Heart Circ Physiol*. 2001; 281:H796–803. [PubMed: 11454584]
59. Stepp DW, Nishikawa Y, Chilian WM. Regulation of shear stress in the canine coronary microcirculation. *Circulation*. 1999; 100:1555–1561. DOI: 10.1161/01.CIR.100.14.1555 [PubMed: 10510060]
60. Stumpe T, Schrader J. Phosphorylation potential, adenosine formation, and critical PO₂ in stimulated rat cardiomyocytes. *Am J Physiol*. 1997; 273:H756–766. [PubMed: 9277493]
61. Tarnow J, Eberlein HJ, Hess W, Schneider E, Schweichel E, Zimmermann G. Hemodynamic interactions of hemodilution, anaesthesia, propranolol pretreatment and hypovolaemia. II: Coronary circulation. *Basic Res Cardiol*. 1979; 74:123–130. DOI: 10.1007/BF01907815 [PubMed: 475722]
62. Thorling EB, Erslev AJ. The “tissue” tension of oxygen and its relation to hematocrit and erythropoiesis. *Blood*. 1968; 31:332–343. [PubMed: 5640631]
63. Tune, JD. Morgan & Claypool Life Sciences. Williston, VT: 2014. Coronary Circulation.
64. Van Woerkens EC, Trouwborst A, Duncker DJ, Koning MM, Boomsma F, Verdouw PD. Catecholamines and regional hemodynamics during isovolemic hemodilution in anesthetized pigs. *J Appl Physiol* (1985). 1992; 72:760–769. [PubMed: 1559956]
65. Van Wylen DG, Williams AG Jr, Downey HF. Interstitial purine metabolites and lactate during regional myocardial hypoxia. *Cardiovasc Res*. 1993; 27:1498–1503. DOI: 10.1093/cvr/27.8.1498 [PubMed: 8221804]
66. Vatner SF, Higgins CB, Franklin D. Regional circulatory adjustments to moderate and severe chronic anemia in conscious dogs at rest and during exercise. *Circ Res*. 1972; 30:731–740. DOI: 10.1161/01.RES.30.6.731 [PubMed: 5025677]
67. von Restorff W, Hofling B, Holtz J, Bassenge E. Effect of increased blood fluidity through hemodilution on coronary circulation at rest and during exercise in dogs. *Pflugers Arch*. 1975; 357:15–24. DOI: 10.1007/BF00584541 [PubMed: 1171454]
68. Wilkerson DK, Rosen AL, Sehgal LR, Gould SA, Sehgal HL, Moss GS. Limits of cardiac compensation in anemic baboons. *Surgery*. 1988; 103:665–670. [PubMed: 3375993]
69. Woodson RD, Auerbach S. Effect of increased oxygen affinity and anemia on cardiac output and its distribution. *J Appl Physiol Respir Environ Exerc Physiol*. 1982; 53:1299–1306. [PubMed: 7174422]
70. Yao X, Chang AY, Boulpaep EL, Segal AS, Desir GV. Molecular cloning of a glibenclamide-sensitive, voltage-gated potassium channel expressed in rabbit kidney. *J Clin Invest*. 1996; 97:2525–2533. DOI: 10.1172/JCI118700 [PubMed: 8647945]
71. Young SH, Stone HL. Effect of a reduction in arterial oxygen content (carbon monoxide) on coronary flow. *Aviat Space Environ Med*. 1976; 47:142–146. [PubMed: 1252205]

Figure 1. Relationship between aortic blood pressure (A), myocardial oxygen consumption (B), coronary blood flow (C) and myocardial oxygen delivery (D) vs. hematocrit for control swine that received volume replacement with saline and Hespan.

Figure 2.
Representative tracing of the effects of decreasing hematocrit on ECG and coronary blood flow over time in untreated control swine that received volume replacement with Hespan.

Figure 3.

Relationship between coronary blood flow (A) and myocardial oxygen delivery (B) vs. aortic pressure, coronary blood flow vs heart rate (C) and myocardial oxygen consumption (D), and coronary venous oxygen partial pressure vs. hematocrit (E) and myocardial oxygen consumption (F) for control swine that received volume replacement with saline and Hespan.

Figure 4.

Relationship between coronary blood flow (A), myocardial oxygen delivery (B), and coronary venous oxygen tension (C) vs. hematocrit and coronary venous oxygen tension vs. myocardial oxygen consumption (D) for control and L-NAME treated swine that received volume replacement with Hespan.

Figure 5.

Relationship between coronary blood flow (A), myocardial oxygen delivery (B), and coronary venous oxygen tension (C) vs. hematocrit and coronary venous oxygen tension vs. myocardial oxygen consumption (D) for control and 4-AP treated swine that received volume replacement with Hespan.

Figure 6.

Relationship between coronary blood flow (A), myocardial oxygen delivery (B), and coronary venous oxygen tension (C) vs. hematocrit and coronary venous oxygen tension vs. myocardial oxygen consumption (D) for vehicle and glibenclamide treated swine that received volume replacement with Hespan.

Control									
	32 ± 1 n = 6	26 ± 1 n = 6	21 ± 1 n = 5	16 ± 1 n = 6	10 ± 1 n = 6	Drug	Hematocrit	Interaction	
Hematocrit (%)									
Sample size									
Arterial oxygen content (ml O ₂ /dl)	14.7 ± 0.4	11.6 ± 0.2 *	9.1 ± 0.2 *	7.0 ± 0.1 *	4.7 ± 0.1 *	N/A	<i>P</i> < 0.001	N/A	N/A
Coronary blood flow (ml/min/g)	0.39 ± 0.05	0.54 ± 0.06	0.79 ± 0.10 *	1.02 ± 0.12 *	1.63 ± 0.16 *	N/A	<i>P</i> < 0.001	N/A	N/A
Mean blood pressure (mmHg)	92 ± 3	89 ± 4	87 ± 4	84 ± 4	81 ± 5	N/A	<i>P</i> = 0.400	N/A	N/A
Heart rate (bpm)	64 ± 6	68 ± 7	82 ± 11	81 ± 7	93 ± 7	N/A	<i>P</i> = 0.070	N/A	N/A
Arterial pH	7.47 ± 0.03	7.51 ± 0.02	7.50 ± 0.02	7.51 ± 0.02	7.49 ± 0.01	N/A	<i>P</i> = 0.563	N/A	N/A
Coronary venous pH	7.40 ± 0.03	7.44 ± 0.02	7.44 ± 0.02	7.42 ± 0.04	7.44 ± 0.02	N/A	<i>P</i> = 0.825	N/A	N/A
Arterial pO ₂ (mmHg)	173 ± 23	177 ± 22	175 ± 25	173 ± 23	173 ± 24	N/A	<i>P</i> = 1.000	N/A	N/A
Coronary venous pO ₂ (mmHg)	19.4 ± 1.8	20.5 ± 1.4	19.5 ± 1.3	18.7 ± 1.7	19.2 ± 1.7	N/A	<i>P</i> = 0.952	N/A	N/A
MVO ₂ (μl O ₂ /min/g)	41 ± 4	42 ± 5	50 ± 6	50 ± 5	55 ± 6	N/A	<i>P</i> = 0.293	N/A	N/A
L-NAME									
Hematocrit (%)	32 ± 2 n = 5	24 ± 1 n = 5	19 ± 1 n = 5	14 ± 1 n = 4	9 ± 1 n = 5	Drug	Hematocrit	Interaction	
Sample size									
Arterial oxygen content (ml O ₂ /dl)	15.3 ± 0.3	11.2 ± 0.3 *	8.9 ± 0.4 *	6.7 ± 0.2 *	4.9 ± 0.1 *	<i>P</i> = 0.851	<i>P</i> < 0.001	<i>P</i> = 0.326	
Coronary blood flow (ml/min/g)	0.42 ± 0.03	0.47 ± 0.02	0.72 ± 0.04 *	1.10 ± 0.12 *	1.63 ± 0.24 *	<i>P</i> = 0.921	<i>P</i> < 0.001	<i>P</i> = 0.958	
Mean blood pressure (mmHg)	124 ± 6 [†]	130 ± 3 [†]	122 ± 7 [†]	117 ± 8 [†]	116 ± 9 [†]	<i>P</i> < 0.001	<i>P</i> = 0.206	<i>P</i> = 0.925	
Heart rate (bpm)	65 ± 5	63 ± 7	75 ± 7	85 ± 6	84 ± 7	<i>P</i> = 0.521	<i>P</i> = 0.005	<i>P</i> = 0.900	
Arterial pH	7.52 ± 0.01	7.54 ± 0.03	7.49 ± 0.02	7.46 ± 0.02	7.44 ± 0.03	<i>P</i> = 0.702	<i>P</i> = 0.157	<i>P</i> = 0.079	
Coronary venous pH	7.45 ± 0.02	7.43 ± 0.01	7.42 ± 0.02	7.37 ± 0.03	7.37 ± 0.04	<i>P</i> = 0.230	<i>P</i> = 0.643	<i>P</i> = 0.250	
Arterial pO ₂ (mmHg)	195 ± 13	194 ± 15	190 ± 14	186 ± 21	185 ± 16	<i>P</i> = 0.241	<i>P</i> = 0.998	<i>P</i> = 0.999	
Coronary venous pO ₂ (mmHg)	16.8 ± 2.4	14.5 ± 2.7 [†]	14.5 ± 1.7	14.7 ± 0.9	18.0 ± 0.7	<i>P</i> = 0.002	<i>P</i> = 0.831	<i>P</i> = 0.681	
MVO ₂ (μl O ₂ /min/g)	50 ± 5	48 ± 4	56 ± 7	68 ± 8	66 ± 10	<i>P</i> = 0.013	<i>P</i> = 0.036	<i>P</i> = 0.868	
4-AP									
Hematocrit (%)	33 ± 1	25 ± 1	20 ± 1	14 ± 2	8 ± 1	Drug	Hematocrit	Interaction	

	Control						
	n = 5	n = 5	n = 4	n = 4	n = 5	n = 4	
Sample size							
Arterial oxygen content (ml O ₂ /dl)	15.1 ± 0.3	11.7 ± 0.4 [*]	9.1 ± 0.3 [*]	7.0 ± 0.3 [*]	4.8 ± 0.2 [*]	P = 0.541	P < 0.001
Coronary blood flow (ml/min/g)	0.37 ± 0.05	0.52 ± 0.06	0.76 ± 0.08	0.98 ± 0.14 [*]	1.52 ± 0.19 [*]	P = 0.524	P < 0.001
Mean blood pressure (mmHg)	90 ± 7	93 ± 7	89 ± 5	98 ± 6	91 ± 5	P = 0.097	P = 0.753
Heart rate (bpm)	68 ± 8	67 ± 5	71 ± 6	73 ± 6	77 ± 5	P = 0.195	P = 0.055
Arterial pH	7.55 ± 0.02 [†]	7.53 ± 0.03	7.55 ± 0.01	7.51 ± 0.03	7.51 ± 0.03	P = 0.018	P = 0.847
Coronary venous pH	7.48 ± 0.03 [†]	7.48 ± 0.02	7.47 ± 0.01	7.47 ± 0.01	7.46 ± 0.01	P = 0.022	P = 0.966
Arterial pO ₂ (mmHg)	176 ± 17	178 ± 15	183 ± 12	206 ± 14	205 ± 9	P = 0.267	P = 0.934
Coronary venous pO ₂ (mmHg)	15.7 ± 1.2	14.3 ± 1.5 [†]	13.3 ± 2.0 [†]	15.5 ± 1.8	16.0 ± 1.5	P < 0.001	P = 0.962
MVO ₂ (μl O ₂ /min/g)	39 ± 3	47 ± 4	53 ± 3	56 ± 8	60 ± 13	P = 0.380	P = 0.049
							P = 0.947

^{*} = $P < 0.05$ vs. baseline hematocrit, same treatment.

[†] = $P < 0.05$ vs. control, same level of hematocrit.

Table 2

Hemodynamic and coronary responses to graded reductions in hematocrit (Hespan replacement) in vehicle and glibenclamide treated swine.

	Glibenclamide Vehicle							Interaction
	Hematocrit (%)	Sample size	Arterial oxygen content (ml O ₂ /dl)	Coronary blood flow (ml/min/g)	Mean blood pressure (mmHg)	Heart rate (bpm)	Arterial pH	
	29 ± 1 n = 4	23 ± 1 n = 3	18 ± 1 n = 4	12 ± 1 n = 3	8 ± 1 n = 4	4.6 ± 0.2 [*]	P = 0.176	P = 0.755
	14.8 ± 0.5	11.4 ± 0.2 [*]	8.7 ± 0.2 [*]	6.4 ± 0.2 [*]	4.6 ± 0.2 [*]	2.00 ± 0.17 [*]	P < 0.001	P = 0.522
	0.53 ± 0.07	0.66 ± 0.07	1.01 ± 0.09 [*]	1.45 ± 0.13 ^{*,†}	98 ± 5 [†]	83 ± 2	P = 0.001	P = 0.799
	100 ± 4	98 ± 5	96 ± 5	100 ± 6 [†]	75 ± 6	7.41 ± 0.01 [†]	P = 0.419	P = 0.911
	69 ± 11	64 ± 2	7.44 ± 0.03	7.37 ± 0.02	7.37 ± 0.02	167 ± 14	P < 0.001	P = 0.345
	7.47 ± 0.04	7.38 ± 0.03	7.38 ± 0.02	7.42 ± 0.02 [†]	7.37 ± 0.02	19.9 ± 0.5 [*]	P = 0.012	P = 0.741
	7.40 ± 0.04	159 ± 26	181 ± 20	127 ± 28	167 ± 14	73 ± 3 [†]	P = 0.366	P = 0.881
	165 ± 29	14.8 ± 0.9 [†]	15.8 ± 0.8	16.3 ± 0.9	19.9 ± 0.5 [*]	80 ± 5 [†]	P = 0.003	P = 0.293
	15.3 ± 1.7	66 ± 5 [†]	76 ± 8 [†]	80 ± 5 [†]	73 ± 3 [†]		P < 0.001	P = 0.847
	66 ± 6 [†]							
Glibenclamide								
	32 ± 1 n = 5	25 ± 1 n = 5	19 ± 1 n = 5	14 ± 1 n = 5	9 ± 1 n = 5			
	14.9 ± 0.4	11.7 ± 0.3 [*]	9.0 ± 0.3 [*]	7.0 ± 0.2 [*]	4.6 ± 0.1 [*]		P = 0.217	P = 0.932
	0.30 ± 0.03 [†]	0.40 ± 0.04 [†]	0.57 ± 0.04 ^{*,†}	0.79 ± 0.05 ^{*,†}	1.12 ± 0.08 ^{*,†}		P < 0.001	P < 0.001
	107 ± 7	102 ± 12	104 ± 10	102 ± 10	94 ± 10		P = 0.541	P = 0.951
	56 ± 7	61 ± 9	64 ± 6	70 ± 7	78 ± 7		P = 0.139	P = 0.960
	7.46 ± 0.04	7.40 ± 0.04	7.39 ± 0.03	7.39 ± 0.03	7.39 ± 0.03		P = 0.213	P = 0.975
	7.37 ± 0.04	7.33 ± 0.04	7.33 ± 0.04	7.33 ± 0.03	7.33 ± 0.03		P = 0.044	P = 0.993
	200 ± 31	209 ± 31	211 ± 30	218 ± 25 [†]	224 ± 21		P = 0.005	P = 0.832
	10.8 ± 1.7 [†]	12.2 ± 1.4	14.0 ± 1.5	15.0 ± 1.0	17.0 ± 1.1 [*]		P = 0.003	P = 0.838
	42 ± 4 [†]	43 ± 4 [†]	45 ± 2 [†]	50 ± 4 [†]	44 ± 4 [†]		P < 0.001	P = 0.913

* = $P < 0.05$ vs. baseline hematocrit, same treatment.

$\ddagger = P < 0.05$ vs. control, same level of hematocrit.
 $\S = P < 0.05$ vs. vehicle, same level of hematocrit.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript